H3C11

Across TCGA pan-cancer cohorts, H3C11 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated H3C11 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher H3C11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated H3C11 expression acts as an unfavorable survival marker.

STAD, DLBC, and CESC are the cancer types where H3C11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.169	0.730	<.001	30	view →
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
CESC	DFS	Median	All	0.203	0.742	<.001	12	view →
HNSC	OS	Median	II,III,IV	0.222	0.710	.031	6	view →
LIHC	OS	Median	All	0.144	0.704	.016	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

H3C11–STAD (OS)

Open the STAD breakdown →